In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Journal title
Antimicrobial agents and chemotherapyDate Published
2014-12Publication Volume
58Publication Issue
3Publication Begin page
1800Publication End page
1
Metadata
Show full item recordAbstract
The in vitro activities of nemonoxacin, levofloxacin, azithromycin, and doxycycline were tested against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae. The MICs at which 90% of the isolates of both C. trachomatis and C. pneumoniae were inhibited (MIC90s) were 0.06 μg/ml (range, 0.03 to 0.13 μg/ml). The minimal bactericidal concentrations at which 90% of the isolates were killed by nemonoxacin (MBC90s) were 0.06 μg/ml for C. trachomatis (range, 0.03 to 0.125 μg/ml) and 0.25 for C. pneumoniae (range, 0.015 to 0.5 μg/ml).Citation
Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58(3):1800-1. doi: 10.1128/AAC.02263-13. Epub 2013 Dec 23. PMID: 24366753; PMCID: PMC3957896.DOI
10.1128/AAC.02263-13ae974a485f413a2113503eed53cd6c53
10.1128/AAC.02263-13
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
- Authors: Kohlhoff SA, Huband MD, Hammerschlag MR
- Issue date: 2014 Dec
- In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
- Authors: Malay S, Roblin PM, Reznik T, Kutlin A, Hammerschlag MR
- Issue date: 2002 Feb
- In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
- Authors: Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR
- Issue date: 2010 Mar
- In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
- Authors: Roblin PM, Hammerschlag MR
- Issue date: 2000 Sep
- In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
- Authors: Roblin PM, Reznik T, Kutlin A, Hammerschlag MR
- Issue date: 2003 Mar